FATEClinical Trials•globenewswire•
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
Sentiment:Positive (70)
Summary
First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition of remission in systemic lupus erythematosus (DORIS) at 12-month follow-up
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by globenewswire